Identifying markers for MPNST to improve diagnosis and surgery
Part of Brain & nervous system, Cancer clinical trials.
This trial collects tissue samples from people with MPNST or neurofibroma during surgery to find metabolic markers that could help diagnose MPNST faster and ensure complete removal of tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are diagnosed with MPNST (a type of nerve tumor) or neurofibroma (a non-cancerous nerve growth).
- You are scheduled for surgery to remove the tumor as part of your usual care.
- You are at least 1 year old.
- Your tumor can be measured (at least 1 cm) on a scan or physical exam.
- You are able to understand and sign a consent form (or have a parent do so if you are under 18).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called BMS-986504 is safe and effective for treating malignant peripheral nerve sheath tumors (MPNST) that cannot be surgically removed. The drug targets a specific genetic change (MTAP deletion) found in these tumors.
This trial tests two targeted drugs, mirdametinib and vorinostat, to see if they can shrink MPNST tumors in people with NF1 before surgery. It is for patients whose tumors lack a specific protein marker (H3K27me3).
This study tracks people with NF1 to watch for when benign nerve tumors turn cancerous. It uses regular MRI scans to catch changes early, which could help guide treatment decisions.
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
This study talks with people who have NF1 (and caregivers of children with NF1) about how visible tumors affect them. The goal is to create questionnaires that measure these concerns, which could lead to better support and treatments.
This study creates an international registry linked to a virtual biobank, so researchers can collect and share information and biological samples for patients with specific peripheral neuroblastic tumors. It may help future research and care planning by improving what scientists know about these conditions.
Hear when a new MPNST trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.